Theratechnologies

CB Biotechnology has completed the acquisition of Theratechnologies for $3.01 per share in cash; shareholders also receive one CVR per share with a maximum additional amount of $1.19, whose market value was most recently estimated at $0.80. Theratechnologies generated $84.38 million in revenue over the last twelve months with a gross profit margin of 77.72%. The stock is expected to be delisted from the TSX and Nasdaq in the near term, and Theratechnologies plans to terminate its reporting obligations in Canada and deregister under the US Securities Exchange Act. » Plus sur de.investing.com

The Quebec Court of Appeal has approved the announced takeover of Theratechnologies by CB Biotechnology, an affiliate of Future Pak, after shareholders had already approved the arrangement plan. Closing is expected on September 25, 2025, subject to remaining closing conditions. The deal provides $3.01 in cash per share plus a contingent value right (CVR) of up to $1.19, which could raise the total to $4.20 per share. Analysts project profitability in 2025; Jones Trading downgraded the stock from buy to hold in connection with the transaction. » Plus sur de.investing.com

Shareholders of Theratechnologies voted in favour of the arrangement with CB Biotechnology, a subsidiary of Future Pak, with 97.44% of votes cast; minority shareholders also supported the plan (97.43%), meeting the requirements of Multilateral Instrument 61-101. The transaction remains subject to judicial approval by the Superior Court of Québec; a hearing is scheduled for 16 September 2025. Closing also depends on Future Pak securing the expected debt financing; financial details were not disclosed. Over the past six months the Theratechnologies share rose 58.82% according to InvestingPro; market capitalization and share price were reported at USD 874 million and USD 8.76, respectively. » Plus sur de.investing.com